Wall Street brokerages expect NxStage Medical, Inc. (NASDAQ:NXTM) to report sales of $108.07 million for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for NxStage Medical’s earnings, with the lowest sales estimate coming in at $106.30 million and the highest estimate coming in at $109.84 million. NxStage Medical posted sales of $97.30 million during the same quarter last year, which would indicate a positive year over year growth rate of 11.1%. The company is scheduled to announce its next quarterly earnings results on Wednesday, November 14th.
On average, analysts expect that NxStage Medical will report full-year sales of $432.81 million for the current fiscal year, with estimates ranging from $429.70 million to $435.91 million. For the next financial year, analysts anticipate that the firm will report sales of $467.80 million, with estimates ranging from $467.30 million to $468.30 million. Zacks’ sales calculations are a mean average based on a survey of research firms that that provide coverage for NxStage Medical.
NxStage Medical (NASDAQ:NXTM) last issued its quarterly earnings data on Tuesday, August 7th. The medical device company reported ($0.04) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.05) by $0.01. NxStage Medical had a negative net margin of 3.67% and a negative return on equity of 7.02%. The company had revenue of $106.97 million during the quarter, compared to the consensus estimate of $105.35 million.
Shares of NXTM stock traded up $0.02 during trading hours on Monday, hitting $29.03. 813,700 shares of the company were exchanged, compared to its average volume of 504,304. NxStage Medical has a 52 week low of $22.70 and a 52 week high of $29.19. The company has a market capitalization of $1.89 billion, a price-to-earnings ratio of -131.95 and a beta of -0.05.
Several hedge funds have recently modified their holdings of the company. BlackRock Inc. grew its position in NxStage Medical by 10.5% in the second quarter. BlackRock Inc. now owns 5,289,606 shares of the medical device company’s stock valued at $147,581,000 after purchasing an additional 501,922 shares in the last quarter. Alpine Associates Management Inc. grew its position in NxStage Medical by 0.9% in the second quarter. Alpine Associates Management Inc. now owns 3,326,982 shares of the medical device company’s stock valued at $93,087,000 after purchasing an additional 30,300 shares in the last quarter. Water Island Capital LLC grew its position in NxStage Medical by 12.6% in the second quarter. Water Island Capital LLC now owns 1,334,420 shares of the medical device company’s stock valued at $37,230,000 after purchasing an additional 149,713 shares in the last quarter. JPMorgan Chase & Co. grew its position in NxStage Medical by 56.3% in the third quarter. JPMorgan Chase & Co. now owns 1,187,250 shares of the medical device company’s stock valued at $33,113,000 after purchasing an additional 427,745 shares in the last quarter. Finally, Northern Trust Corp grew its position in NxStage Medical by 3.0% in the second quarter. Northern Trust Corp now owns 885,227 shares of the medical device company’s stock valued at $24,697,000 after purchasing an additional 25,633 shares in the last quarter. 83.15% of the stock is owned by institutional investors.
NxStage Medical Company Profile
NxStage Medical, Inc, a medical technology company, develops, manufactures, and markets products and services for patients suffering from chronic or acute kidney failure. Its primary product includes the System One, a portable hemodialysis system, which is used primarily for home hemodialysis and a range of dialysis therapies to deliver in the home setting.
Recommended Story: Rule of 72
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NxStage Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical and related companies with MarketBeat.com's FREE daily email newsletter.